News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Bank of Russia cuts key rate 25 bps to 14.25%, signaling cautious easing despite fuel-production disruptions and looser fiscal plans.
  • RBI minutes show unanimous hold at a 5.25% repo rate and a neutral stance amid oil, rupee, and weather risks to inflation.
  • Sterling steadies above $1.32 after stronger retail sales, but political strain leaves the pound near two-month lows.
  • Cognizant (CTSH) flagged as a tactical long after shares fell near 52-week lows, citing strong free cash flow and high short interest.
  • DHI Group (DHX) touted as an opportunistic long for its cash-generation and low valuation with defined stop and target levels.
  • Lite Strategy will speak at the Litecoin Foundation Summit, underscoring institutional adoption after adopting Litecoin as its primary treasury asset.
  • West Bancorporation schedules Q2 results and a July 23 conference call, adding to regional-bank earnings flow.

Latest Articles

Bending Spoons Files F-1 to Pursue Nasdaq Listing Under 'BSP' Ticker

Bending Spoons Files F-1 to Pursue Nasdaq Listing Under 'BSP' Ticker

Bending Spoons S.p.A. has submitted a registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a potential initial public offering of its ordinary shares, seeking a listing on the Nasdaq Global Select Market under the symbol BSP. The company named a group of international banks as lead and joint book-running managers.…

Quantum Space to List via SPAC Merger in $1.2 Billion Deal

Quantum Space to List via SPAC Merger in $1.2 Billion Deal

Quantum Space has agreed to merge with SPAC Inflection Point Acquisition in a transaction that values the combined business at roughly $1.2 billion. The agreement includes a $300 million PIPE led by Inflection Point Asset Management and is intended to fund acceleration of the company's Ranger spacecraft program and expansion of manufacturing capaci…

Remy Cointreau Shares Rise After UBS Upgrades Stock on RC Forward Plan

Remy Cointreau Shares Rise After UBS Upgrades Stock on RC Forward Plan

Remy Cointreau shares climbed nearly 4% after UBS upgraded the stock to neutral from sell and raised its 12-month price target to €44. The move follows the announcement of the RC Forward transformation plan and full-year results showing mixed performance: top-line pressure, an EBIT beat, improved cash conversion, and a halved dividend.

Campbell’s Sticks to Annual Forecast as Consumer Caution Dampens Sales

Campbell’s Sticks to Annual Forecast as Consumer Caution Dampens Sales

Campbell’s Co reiterated its full-year guidance after reporting a 4% drop in third-quarter net sales, as subdued U.S. consumer spending and movement toward lower-cost and private-label brands weighed on demand. The company’s adjusted quarterly EPS beat estimates thanks to supply-chain optimization and cost-savings initiatives, but management expect…

Bank of America Sees Blurring Lines Between Betting, Crypto and Finance

Bank of America Sees Blurring Lines Between Betting, Crypto and Finance

Bank of America analysts say the distinctions between sports wagering, speculative crypto trading, and traditional financial markets are fading. The bank identifies perpetual futures and increased gamification on prediction platforms and sportsbooks as near-term areas of innovation that could open new revenue streams for betting operators.

Axolotls Flood Mexico City Imagery as World Cup Arrivals Begin

Axolotls Flood Mexico City Imagery as World Cup Arrivals Begin

As Mexico City prepares to host five World Cup matches, the axolotl - a salamander native to the region - has surfaced across murals, subway cars and public sculptures in vibrant purple. The animal's sudden prominence has produced mixed reactions: vendors and some visitors view the imagery as an opportunity to raise awareness, while local scientist…

Lilly stock rises as retatrutide data bolsters obesity franchise lead

Lilly stock rises as retatrutide data bolsters obesity franchise lead

Eli Lilly shares rose ahead of the market after the company released complete results from two retatrutide trials at the American Diabetes Association meeting. The lower 4 mg dose produced roughly 19% weight loss with tolerability comparable to existing therapies, prompting analysts to say the drug could strengthen Lilly’s leadership in the obesity…

Cerebras Shares Climb as Nine Banks Begin Buy-Focused Coverage

Cerebras Shares Climb as Nine Banks Begin Buy-Focused Coverage

Cerebras Systems (NASDAQ: CBRS) rose 4% after nine major brokerages initiated coverage following the end of the company's post-IPO quiet period. Analysts emphasized Cerebras' wafer-scale Wafer-Scale Engine (WSE), its advantage in fast inference, and sizable commercial contracts with OpenAI and AWS as the basis for aggressive revenue and market-size…

Cognizant Shares Rise After Wedbush Upgrade Citing AI Builder Momentum

Cognizant Shares Rise After Wedbush Upgrade Citing AI Builder Momentum

Cognizant Technology Solutions jumped in pre-market trading after Wedbush upgraded the stock to Outperform and boosted its price target from $56 to $70. The broker highlighted accelerating traction for Cognizant's AI Builder initiative, a 70% increase in total contract value and the prospect that large enterprise deals will convert to revenue in th…

Why Broadcom's Pullback Is a Buying Opportunity, Not a Breakdown

Why Broadcom's Pullback Is a Buying Opportunity, Not a Breakdown

Broadcom (AVGO) has pulled back sharply, but beneath the headline volatility the company retains durable secular advantages, strong free cash flow, and enterprise exposure that should support a recovery. This is a tactical long trade that aims to capture mean reversion into value and upcoming catalysts while keeping position risk-defined.

BofA: Another 2% Drop in Nasdaq Could Force Wider CTA Liquidations

BofA: Another 2% Drop in Nasdaq Could Force Wider CTA Liquidations

Bank of America warns that Friday's steep fall in the Nasdaq-100 appears to have initiated a coordinated reduction in systematic long equity exposures, and that an additional decline of roughly 90 basis points to 2% could prompt broader CTA deleveraging. The bank highlights record selling from leveraged and inverse ETFs, historically elevated SPX g…

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

Kymera Therapeutics announced new preclinical data for KT-579, an oral IRF5 degrader showing disease-modifying effects in lupus models by targeting multiple inflammatory pathways. The ongoing Phase 1 trial in healthy volunteers aims to assess safety and biological activity, with results anticipated in the second half of 2026. Success could pave the…

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

Tonix Pharmaceuticals announced it has secured a second commercial payer agreement effective June 1, 2026, with a leading group purchasing organization (GPO), increasing commercial insurance coverage of its fibromyalgia drug TONMYA® to approximately 52 million U.S. lives. This milestone follows an earlier agreement and enhances patient access to th…

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

Mineralys Therapeutics announced new late-breaking data from its Phase 2 and Phase 3 trials showing that lorundrostat, a selective aldosterone synthase inhibitor, modulates heart failure risk biomarkers in patients with uncontrolled hypertension. The data will be presented at the Endocrine Society's annual meeting, highlighting lorundrostat's effic…